In a 5-year follow-up to the phase III ExteNET trial of women with HER2-positive stage I-IIIc operable breast cancer, investigators found that extended adjuvant therapy with neratinib (Nerlynx) significantly reduced the proportion of clinically relevant breast cancer relapses without increasing the risk of long-term toxicity.
Other gastrointestinal-related adverse events included nausea (43%), fatigue (27%), vomiting (26%), and abdominal pain (24%). In the placebo arm, 36% of patients had all-grade diarrhea, with a grade 3/4 incidence of 2.0%.
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18:1688-700.
... to read the full story